MicroPort CardioFlow Medtech マネジメント

マネジメント基準チェック /34

現在、CEO に関する十分な情報がありません。

主要情報

Jeffrey R Lindstrom

最高経営責任者

CN¥4.0m

報酬総額

CEO給与比率	59.8%
CEO在任期間	1.2yrs
CEOの所有権	n/a
経営陣の平均在職期間	4yrs
取締役会の平均在任期間	3.8yrs

経営陣の近況

Recent updates

CEO報酬分析

MicroPort CardioFlow Medtech の収益と比較して、Jeffrey R Lindstrom の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-CN¥349m
Mar 31 2024	n/a	n/a	-CN¥410m
Dec 31 2023	CN¥4m	CN¥2m	-CN¥472m

報酬と市場: Jeffrey Rの総報酬 ($USD 562.75K ) は、 German市場 ($USD 816.84K ) の同様の規模の企業の平均を下回っています。

報酬と収益: Jeffrey Rの報酬と会社の業績を比較するにはデータが不十分です。

CEO（最高経営責任者

Jeffrey R Lindstrom (57 yo)

1.2yrs

在職期間

CN¥4,004,000

報酬

Mr. Jeffrey R Lindstrom is President, Executive Director & General Manager of MicroPort CardioFlow Medtech Corporation from August 29, 2023. He served as senior director of engineering in Edwards Lifescien...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Jeffrey R Lindstrom	President	1.2yrs	CN¥4.00m	データなし
Liang Zhao	Executive Director & First VP of Total Solutions	2.4yrs	CN¥3.91m	0.058% € 123.6k
Luying Yan	VP & Executive Director	4.1yrs	CN¥2.70m	0.042% € 88.8k
Xiangmei Li	Joint Company Secretary	4yrs	データなし	データなし
Lok Yee Chan	Joint Company Secretary	4yrs	データなし	データなし

4.0yrs

平均在職期間

43yo

平均年齢

経験豊富な経営陣: 72Xの経営陣は経験豊富であると考えられます ( 4年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Jeffrey R Lindstrom	President	1.2yrs	CN¥4.00m	データなし
Liang Zhao	Executive Director & First VP of Total Solutions	2.4yrs	CN¥3.91m	0.058% € 123.6k
Luying Yan	VP & Executive Director	4.1yrs	CN¥2.70m	0.042% € 88.8k
Jonathan H. Chou	Independent Non-Executive Director	3.8yrs	CN¥254.00k	データなし
Xia Wu	Non-Executive Director	5.2yrs	データなし	データなし
Guoming Chen	Non-Executive Chairman of the Board	4.1yrs	CN¥3.16m	0.031% € 65.1k
Junjie Zhang	Non-Executive Director	5.2yrs	データなし	データなし
Zhixiang Sun	Independent Non-Executive Director	3.8yrs	CN¥254.00k	データなし
Jiandong Ding	Independent Non-Executive Director	3.2yrs	CN¥254.00k	0.0012% € 2.6k

3.8yrs

平均在職期間

47yo

平均年齢

経験豊富なボード: 72Xの取締役会は経験豊富であると考えられます ( 3.8年の平均在任期間)。

MicroPort CardioFlow Medtech マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 26, 2024

MicroPort Cardioflow Medtech Corporation Announces Executive Changes

Less than half of directors are independent

Less than half of directors are independent

MicroPort CardioFlow Medtech Announces Appointment of Zhao Liang as Executive Director

MicroPort CardioFlow Medtech Corporation Announces Resignation of Wu Guojia as an Executive Director

Recent updates

Now 22% undervalued after recent price drop

Now 28% undervalued

First half 2024 earnings released: CN¥0.024 loss per share (vs CN¥0.076 loss in 1H 2023)

Now 56% undervalued after recent price drop

MicroPort CardioFlow Medtech Corporation to Report First Half, 2024 Results on Aug 28, 2024

Now 48% undervalued after recent price drop

Full year 2023 earnings released: CN¥0.20 loss per share (vs CN¥0.19 loss in FY 2022)

Forecast to breakeven in 2026

MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 26, 2024

Full year 2023 earnings released: CN¥0.20 loss per share (vs CN¥0.19 loss in FY 2022)

MicroPort CardioFlow Medtech Corporation to Report Fiscal Year 2023 Results on Mar 27, 2024

Microport Cardioflow Medtech Corporation Receives NMPA Approval for Registration Application of Anchorman LAAC System

MicroPort CardioFlow Medtech Corporation Completes Clinical Implantation Cases in Europe

MicroPort CardioFlow Medtech Corporation Announces First Two Clinical Applications of Third-Generation TAVI Product

First half 2023 earnings released: CN¥0.076 loss per share (vs CN¥0.052 loss in 1H 2022)

MicroPort Cardioflow Medtech Corporation Announces Executive Changes

MicroPort CardioFlow Medtech Corporation to Report First Half, 2023 Results on Aug 29, 2023

New major risk - Share price stability

New minor risk - Share price stability

Less than half of directors are independent

Full year 2022 earnings released: CN¥0.19 loss per share (vs CN¥0.079 loss in FY 2021)

Less than half of directors are independent

Microport Cardioflow Medtech Corporation Announces Registration in Colombia for Alwide Plus Balloon Catheter

First half 2022 earnings released: CN¥0.05 loss per share (vs CN¥0.031 loss in 1H 2021)

MicroPort CardioFlow Medtech Corporation to Report Q2, 2022 Results on Aug 29, 2022

MicroPort CardioFlow Medtech Corporation Provides Earnings Guidance for the Six Months Ended June 30, 2022

Microport Cardioflow Medtech Corporation Announces That the Transcatheter Mitral Valve Replacement System Independently Developed by the Group Was Successfully Applied by the Heart Team of Zhongshan Hospital

MicroPort CardioFlow Medtech Announces Appointment of Zhao Liang as Executive Director

Full year 2021 earnings released: CN¥0.079 loss per share (vs CN¥0.23 loss in FY 2020)

MicroPort CardioFlow Medtech Corporation Announces Resignation of Wu Guojia as an Executive Director

Less than half of directors are independent

Full year 2021 earnings released: CN¥0.08 loss per share (vs CN¥0.23 loss in FY 2020)

MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 22, 2022

MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 22, 2022

Microport Cardioflow Medtech Corporation Successfully Registered Vitaflow Liberty Transcatheter Aortic Valve Implantation System in Argentina

Microport Cardioflow Medtech Corporation Announces Ce Mark Registration Application for Vitaflow Libertytm

No longer forecast to breakeven

Forecast to breakeven in 2023

Independent Non-Executive Director Hualiang Jiang has left the company

MicroPort CardioFlow Medtech Corporation to Report Fiscal Year 2020 Results on Mar 30, 2021

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /34